Balsalazide

Summary

Balsalazide (CHEMBL1201346) is an approved small-molecule prodrug (ATC A07EC04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07EC04
• Clinical trials: 2
• Chemistry: 357.32 Da · C17H15N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201346
Name	Balsalazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54585
ChEBI	CHEBI:267413
ATC	A07EC04
Molecular formula	C17H15N3O6
Molecular weight	357.32
InChIKey	IPOKCKJONYRRHP-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O

IUPAC name: 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid

ChEBI definition: A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-β-alanine via an azo bond.

Pharmacological roles (ChEBI): prodrug, non-steroidal anti-inflammatory drug, anti-ulcer drug, gastrointestinal drug.

Also known as: Balsalazida, Balsalazide, balsalazide, BALSALAZIDE, SID144205805, SID170465305

Parent form; salt/anhydrous children: CHEMBL1200760

Patent coverage: 1,995 distinct patent families (8,319 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,286 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Vasopressin V2 receptor, Vasopressin V1a receptor, 5-hydroxytryptamine receptor 3A, Equilibrative nucleoside transporter 1, Muscarinic acetylcholine receptor M1, NAD-dependent protein deacylase sirtuin-5, mitochondrial, Type-1 angiotensin II receptor, Sodium-dependent serotonin transporter, Adenosine receptor A2a, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SIRT5	5.41	IC50	3900	nM	CHEMBL_ACT_22986890
SIRT5	5.41	IC50	3900	nM	CHEMBL_ACT_23250013
SIRT5	5.41	IC50	3900	nM	CHEMBL_ACT_24824597
SIRT5	5.28	IC50	5300	nM	CHEMBL_ACT_22986840
SIRT5	5.28	IC50	5300	nM	CHEMBL_ACT_24743238
SIRT5	5.28	IC50	5300	nM	CHEMBL_ACT_25612203
SIRT5	5.06	EC50	8800	nM	CHEMBL_ACT_24743298

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00618202	Not specified	COMPLETED	A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions
NCT00618228	Not specified	COMPLETED	Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).